[1]朱卫华,刘继斌.血浆相关基因甲基化在食管癌复发中的临床价值[J].现代检验医学杂志,2016,31(04):93-94,97.[doi:10.3969/j.issn.16717-414.2016.04.025]
　ZHU Wei-hua,LIU Ji-bin.Clinical Significance of Promoter Hypermethylation of Esophageal Squamous Cell Carcinoma(ESCC)in Plasma[J].Journal of Modern Laboratory Medicine,2016,31(04):93-94,97.[doi:10.3969/j.issn.16717-414.2016.04.025]
点击复制

血浆相关基因甲基化在食管癌复发中的临床价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年04期
页码:
93-94,97
栏目:
论著
出版日期:
2016-08-10

文章信息/Info

Title:
Clinical Significance of Promoter Hypermethylation of Esophageal Squamous Cell Carcinoma(ESCC)in Plasma
文章编号:
1671-7414(2016)04-093-03
作者:
朱卫华; 刘继斌
南通市肿瘤医院,江苏南通 226361
Author(s):
ZHU Wei-hua; LIU Ji-bin
Nantong Tumor Hospital,Jiangsu Nantong 226361,China
关键词:
食管癌;  甲基化;  复发
分类号:
R735.1; R730.43
DOI:
10.3969/j.issn.16717-414.2016.04.025
文献标志码:
A
摘要:
目的 评估血浆相关基因甲基化在食管癌复发中的临床价值。方法 收集81例食管癌(ESCC)患者及60例健康体检者血浆。采用甲基化特异性PCR技术分析了81例食管癌患者及60例健康体检者血浆中四个基因SFRP-1,WIF-1,DKK-3和RUNX3启动子区域的甲基化。结果 这四种基因在食管癌血浆甲基化频率均超过25%,其中:SFRP-1为29.6%,WIF-1 35.8%,DKK-3 37.4%,RUNX-3 35.8%; 健康体检者血浆中均未检测到相关基因的甲基化。食管癌患者血浆中SFRP-1(χ2=14.16,P<0.01),DKK-3(χ2=6.21,P<0.05)和RUNX3(χ2=11.75,P<0.01)基因甲基化明显与食管癌的复发有关,未发现WIF-1基因甲基化与食管癌复发有关(χ2=3.39,P>0.05)。结论 食管癌血浆相关基因甲基化可能与食管癌复发相关。
Abstract:
Objective To evaluate the clinical significanceof promoter hypermethylation of esophageal squamous cell carcinoma(ESCC)in plasma.Methods Promoter hypermethylation status of 81 ESCCpatients and 60 healthy persons were analyzed using a methylation marker panel in plasma with methylation-specific polymerase chain reaction and the association between promoter hypermethylation and the two-year recurrence of ESCC.Examined genes included SFRP-1,WIF-1,DKK-3 and RUNX3.Results The frequencies of high-level methylation in ESCC plasma were at least 25%for the four genes:SFRP-1 29.6%,WIF-1 35.8%,DKK-3 37.4% and RUNX-335.8%.Hypermethylation status was not detected in plasma of healthy persons.Hypermethylation of SFRP-1(χ2=14.16,P<0.01),DKK-3(χ2=6.21,P<0.05)and RUNX-3(χ2=11.75,P<0.01)was significantly associated with an increased risk of ESCC recurrence.Conclusion The status of promoter hypermethylation of examined genes in plasma may be associated with recurrence of ESCC.

参考文献/References:

[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancerin 2008: GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
[4] Zhang XM,Guo MZ.The value of epigenetic markers in esophageal cancer[J].Front Med China,2010,4(4):378-384.
[5] Hamilton JP,Sato F,Jin Z,et al.Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression[J].Clin Cancer Res,2006,12(22):6637-6642.
[6] Hamilton JP,Sato F,Greenwald BD,et al.Promoter methylation and response to chemotherapy and radiation in esophageal cancer[J].Clin Gastroenterol Hepatol,2006,4(6):701-708.
[7] 陆海一,林 兰,刘继斌.拮抗Wnt信号通路的CPG岛甲基化表型在肝癌预后中的临床价值[J].现代检验医学杂志,2013,28(6):22-25. Lu HY,Lin L,Liu JB.Clinical significance of CpG island methylator phenotype(CIMP)in plasma associated with prognosis in hepatocellular carcinoma[J].Journal of Modern Laboratory Medicine,2013,28(6):22-25.
[8] Salazar F,Molina MA,Sanchez-Ronco M,et al.First-line therapy andmethylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients[J].Lung Cancer,2011,72(1):84-91.
[9] Cao B,Yang W,Jin Y,et al.Silencing NKD2 by promoter region hypermethylation promotes esophageal cancer progression by activating Wt signaling[J].Journal of Thoracic Oncology,2016[Epub ahead of print].
[10] Ma K,Cao B,Guo M.The detective,prognostic,and predictive value of DNA methylation in human esophageal squamous cell carcinoma[J].Clin Epigenetics,2016,8(1):1-9.

相似文献/References:

[1]马丽颜,梁 静,周建龙.腺瘤样结肠息肉易感基因(APC)及结直肠癌缺失基因(DCC)基因甲基化在肺癌早期诊断的意义[J].现代检验医学杂志,2016,31(01):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
　MA Li-yan,LIANG Jing,ZHOU Jian-long.Evaluation of the Combination of APC and DCC Gene Methylation in the Early Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
[2]张 振,李 力,徐翠香,等.血清TAM和Cyfra21-1检测在食管癌诊断和化疗疗效判定中的价值[J].现代检验医学杂志,2015,30(04):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
　ZHANG Zhen,LI Li,X(¨overU)Cui-xiang,et al.Value of Detecting Serum TAM and Cyfra21-1 Levels in the Diagnosis and Chemotherapeutic Efficacy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
[3]李 璐,梁 辉a,陈群蓉b.鼻咽癌组织中SYK基因启动子区的甲基化分析[J].现代检验医学杂志,2015,30(02):39.[doi:10.3969/j.issn.1671-7414.2015.02.012]
　LI Lu,LIANG Huia,CHEN Qun-rongb.Methylation of SYK Gene Promoter Region in Nasopharyngeal Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):39.[doi:10.3969/j.issn.1671-7414.2015.02.012]
[4]肖小平,张 熊sub>a,秦光明b.食管癌和良性食管疾病患者血浆miRNA-21和miRNA-143检测的临床应用研究[J].现代检验医学杂志,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
　XIAO Xiao-ping,ZHANG Xionga,QIN Guang-mingb.Clinical Research of Detecting Plasma MiRNA-21 and MiRNA-143 for Identifying Early Esophageal Cancer and Benign Esophageal Diseases[J].Journal of Modern Laboratory Medicine,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
[5]邱 巍,胡 威,赵建江,等.江苏宿迁地区汉族人群DNMT3B基因启动子区-149C>T和-579G>T多态性与食管癌易感性的分析[J].现代检验医学杂志,2018,33(02):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　QIU Wei,HU Wei,ZHAO Jian-jiang,et al.Study on the Promoter Region -149C>T and -579G>T Polymorphism of DNMT3B with Genetic Susceptibility to Esophageal Cancer of Han Population in Jiangsu Suqian[J].Journal of Modern Laboratory Medicine,2018,33(04):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]陈　津,彭　伟,崔兆磊,等.食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估[J].现代检验医学杂志,2020,35(03):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
　CHEN Jin,PENG Wei,CUI Zhao-lei,et al.Serum KL-6 Predicts the Risk of Pneumonitis Induction after Radiotherapy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
[7]梁晓虎,郭俊霞,雷尚昆.食管癌组织中lnc RNA DNAJC3-AS1的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
　LIANG Xiao-hu,GUO Jun-xia,LEI Shangkun.Expression of Lnc RNA DNAJC3-AS1 in Esophageal Carcinoma Tissues and Its Correlation with Clinicopathological Features[J].Journal of Modern Laboratory Medicine,2021,36(04):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
[8]朱　娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
　ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(04):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[9]贾东辉,杜　宇,黄　飞,等.食管癌患者行根治性切除术后血清miR-216a和Bcl-2mRNA表达水平及与预后的相关性研究[J].现代检验医学杂志,2022,37(02):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
　JIA Dong-hui,DU Yu,HUANG Fei,et al.Expression Levels of Serum miR-216a and Bcl-2 mRNA and Their Correlation with Prognosis in Patients with Esophageal Cancer after Radical Resection[J].Journal of Modern Laboratory Medicine,2022,37(04):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
[10]刘 伟a,周 杨a,边 超a,等.miR-495 对食管癌细胞株Eca109 在不同放射剂量和顺铂浓度作用的影响及机制研究[J].现代检验医学杂志,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
　LIU Weia,ZHOU Yanga,BIAN Chaoa,et al.Effect of miR-495 on Esophageal Cancer Cell Line Eca109 at Different Radiation Doses and Cisplatin Concentrations and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]

备注/Memo

备注/Memo:

作者简介:朱卫华(1977-),男,学士,主管技师,主要从事肿瘤临床检验及科研工作,Tel:0513-86712063,E-mail:1585543600@qq.com。
通讯作者:刘继斌,Tel:0513-86712016,E-mail:tians2008@163.com。
更新日期/Last Update: 2016-08-10